Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

588.66 +15.51 (+2.71%)
Streaming Delayed Price Updated: 12:28 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,108
Open 579.67
Bid (Size) 586.43 (40)
Ask (Size) 589.89 (40)
Prev. Close 573.15
Today's Range 570.50 - 592.88
52wk Range 265.00 - 605.00
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance

Performance

YTD
+87.6%
+87.6%
1 Month
+42.8%
+42.8%
3 Month
+35.0%
+35.0%
6 Month
+107.0%
+107.0%
1 Year
+84.8%
+84.8%

More News

Read More
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗
Via Stocktwits
News headline image
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Via Benzinga
News headline image
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗
Via Benzinga
News headline image
Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge ↗
Via Chartmill
News headline image
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast ↗
Via Benzinga
News headline image
Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock ↗
Via Benzinga
News headline image
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts ↗
Via Benzinga
News headline image
MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template ↗
Via Chartmill
News headline image
MarketBeat Week in Review – 09/08 - 09/12 ↗
Via MarketBeat
Topics Economy
News headline image
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts ↗
Via Benzinga
News headline image
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure ↗
Via Investor's Business Daily
News headline image
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗
Via Benzinga
News headline image
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma ↗
Via Investor's Business Daily
News headline image
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease ↗
Via Benzinga

Frequently Asked Questions

Is Madrigal Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Madrigal Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Madrigal Pharmaceuticals, Inc. - Common Stock trade on?
Madrigal Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Madrigal Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Madrigal Pharmaceuticals, Inc. - Common Stock is MDGL on the Nasdaq Stock Market
What is the current price of Madrigal Pharmaceuticals, Inc. - Common Stock?
The current price of Madrigal Pharmaceuticals, Inc. - Common Stock is 588.66
When was Madrigal Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Madrigal Pharmaceuticals, Inc. - Common Stock was at 12/03/25 12:28 PM ET
What is the market capitalization of Madrigal Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Madrigal Pharmaceuticals, Inc. - Common Stock is 10.07B
How many shares of Madrigal Pharmaceuticals, Inc. - Common Stock are outstanding?
Madrigal Pharmaceuticals, Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.